1. Home
  2. ABUS vs MRLN Comparison

ABUS vs MRLN Comparison

Compare ABUS & MRLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.31

Market Cap

929.6M

Sector

Health Care

ML Signal

HOLD

MRLN

Merlin Inc. Common Stock

N/A

Current Price

$7.12

Market Cap

915.1M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ABUS
MRLN
Founded
2005
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
929.6M
915.1M
IPO Year
2008
2024

Fundamental Metrics

Financial Performance
Metric
ABUS
MRLN
Price
$4.31
$7.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$5.00
$25.00
AVG Volume (30 Days)
1.7M
1.3M
Earning Date
05-14-2026
10-28-2021
Dividend Yield
N/A
N/A
EPS Growth
55.26
N/A
EPS
0.87
N/A
Revenue
$14,083,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$239.71
N/A
P/E Ratio
$4.95
N/A
Revenue Growth
128.21
N/A
52 Week Low
$3.04
$5.88
52 Week High
$5.10
$17.00

Technical Indicators

Market Signals
Indicator
ABUS
MRLN
Relative Strength Index (RSI) 47.54 38.32
Support Level $4.17 $6.22
Resistance Level $4.62 $17.00
Average True Range (ATR) 0.16 1.24
MACD 0.00 -0.37
Stochastic Oscillator 55.66 10.00

Price Performance

Historical Comparison
ABUS
MRLN

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About MRLN Merlin Inc. Common Stock

Merlin Inc is focused on developing autonomous flight software for legacy and next-generation airborne systems. Its aircraft-agnostic, AI-based software supports takeoff-to-landing autonomous operations for military and civil aviation programs. The company aims to build an AI-based operating software platform intended to support autonomous flight operations across a range of aircraft types.

Share on Social Networks: